Raksha bivalent

Raksha bivalent
Product Description

Each dose contains: bivalent FMD inactivated antigens of O and A strains adsorbed on to aluminium hydroxide gel. Saponin added as adjuvant chlorofom B.P as preservative 0.015mL, phosphate buffer diluent q.s

Indian Immunologicals Ltd

  • IN
  • 2019
    On CPHI since
  • 1000 - 4999
    Employees
Company types
Biopharmaceutical company
Manufacturer/Innovator

Indian Immunologicals Ltd

  • IN
  • 2019
    On CPHI since
  • 1000 - 4999
    Employees
Company types
Biopharmaceutical company
Manufacturer/Innovator

More Products from Indian Immunologicals Ltd (56)

  • Posi-FMD

    Product Posi-FMD

    Each dose contains: monovalent FMD inactivated antigens of O strain adsorbed on to aluminium hydroxide gel. Mineral oil added as adjuvant thiomersal B.P as preservative ≤ 0.02% w/v, phosphate buffer diluent q.s
  • Prazital Forte (Praziquintal , Fenbendazole and Pyrantel Parmate

    Product Prazital Forte (Praziquintal , Fenbendazole and Pyrantel Parmate

    Prazital is a formidable combination of Praziquantel and Pyrantel Pamoate and it offers assured elimination of roundworms, hookworms, ascarides and tapeworms.
  • Rabies veterinary concentrated bulk antigen -inactivated

    Product Rabies veterinary concentrated bulk antigen -inactivated

    Rabies veterinary antigen strain-CVS thiomersal ≤ 0.01% w/v added as preservative and cell growth medium q.s
  • Rabisure

    Product Rabisure

    Each 1mL contains: inactivayted rabies viral antigen of potency ≥1.0IU [rabies virus strain CVS propagated on BHK cells ] adsorbed on to aluminium hydroxide gel, thiomersal B.P as preservative ≤0.02% w/v, phosphate buffer diluent q.s to 1mL
  • Raksha -BT

    Product Raksha -BT

    blue tongue vaccine, inactivated Each dose (2mL) contains: BTV-01 strain (mean antibody titre ≥ 1:20) , BTV-02 strain (mean antibody titre ≥ 1:20), BTV-10 strain (mean antibody titre ≥ 1:20), BTV-16 strain (mean antibody titre ≥ 1:20), BTV-23 strain (mean antibody titre ≥ 1:20), sodium thiosulphate solut...
  • Raksha HS + BQ Haemorrhagic Septicaemia + Black Quarter vaccine

    Product Raksha HS + BQ Haemorrhagic Septicaemia + Black Quarter vaccine

    Raksha-HS+BQ vaccine contains formalin inactivated cultures of Pasteurella multocida and Clostridium chauvoei adjuvanted with aluminium hydroxide gel
  • Raksha Ovac Bivalent

    Product Raksha Ovac Bivalent

    Each dose contains: bivalent FMD inactivated antigens of O and Asia-1 strains adsorbed on to aluminium hydroxide gel. Mineral oil added as adjuvant thiomersal B.P as preservative ≤ 0.02% w/v, phosphate buffer diluent q.s
  • Raksha Ovac Monovalent

    Product Raksha Ovac Monovalent

    Each dose contains: monovalent FMD inactivated antigens of Asia-1 strain adsorbed on to aluminium hydroxide gel. Mineral oil added as adjuvant thiomersal B.P as preservative ≤ 0.02% w/v, phosphate buffer diluent q.s
  • Raksha Ovac trivalent

    Product Raksha Ovac trivalent

    Each dose contains: trivalent FMD inactivated antigens of O, A and Asia-1 strains adsorbed on to aluminium hydroxide gel. Mineral oil added as adjuvant thiomersal B.P as preservative ≤ 0.02% w/v, phosphate buffer diluent q.s
  • Raksha SP + PPR freeze dried

    Product Raksha SP + PPR freeze dried

    sheep pox + PPR vaccine (Peste des Petits ruminants vaccine) composition: Each 1mL contains: sheep pox virus titer ≥ 10TCID50 [propagated on Vero cells] PPr virus titer ≥ 102.5 TCID50 [propagated on Vero cells], sucrose and lactalbumin hydrolysate addes as stabilizers. sterile diluent: Each 1mL contains...
  • Raksha Trivalent

    Product Raksha Trivalent

    Each dose contains: FMD inactivated antigens of O, A and Asia-1 strains adsorbed on to aluminium hydroxide gel. Saponin added as adjuvant chlorofom B.P as preservative 0.015mL, phosphate buffer diluent q.s

Indian Immunologicals Ltd resources (2)

  • News COVID-19 VACCINE DEVELOPMENT

    Indian Immunologicals Limited, in collaboaration with Griffith University, Australia is going to commence research for developing a vaccine for Corona virus, the pandemic which has infected more than two million and killed about 250,00 people across the world. 

    Even WHO has considered the same in its latest draft landscape of COVID 19 vaccine candidates dated 30th April, 2020.